Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fondaparinux Sodium

FDA-approved product (solution, subcutaneous), marketed as Arixtra, Fondaparinux Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fondaparinux Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Deep vein thrombosis
  • Intermediate coronary syndrome
  • Myocardial infarction
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antithrombotic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fondaparinux Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fondaparinux Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy

    NCT00377091 · start 2007-06

    Registered record
    Registry ID
    NCT00377091
    Conditions
    Pulmonary Embolism
    Interventions
    Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2007-06
    Completion
    2007-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Embolism
    InterventionFondaparinux
    PhasePhase 4
    Registry statusWithdrawn

  • Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI

    NCT00464087 · start 2007-06

    Registered record
    Registry ID
    NCT00464087
    Conditions
    Acute Coronary Syndromes
    Interventions
    Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-06
    Completion
    2010-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndromes
    InterventionSwitching from Fondaparinux to Bivalirudin or Unfractionated Heparin
    PhasePhase 3
    Registry statusCompleted

  • Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients

    NCT00510432 · start 2007-04

    Registered record
    Registry ID
    NCT00510432
    Conditions
    Allergy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2007-04
    Completion
    2009-01
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

    NCT00443053 · start 2007-03

    Registered record
    Registry ID
    NCT00443053
    Conditions
    Thrombosis, Venous
    Interventions
    Fondaparinux 2.5mg or placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2009-07
    Enrolment
    3,002

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombosis, Venous
    InterventionFondaparinux 2.5mg or placebo
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication

    NCT00424281 · start 2007-02

    Registered record
    Registry ID
    NCT00424281
    Conditions
    ICU Patients 18 Years or Older.
    Interventions
    Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2007-02
    Completion
    2010-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionICU Patients 18 Years or Older.
    InterventionArixtra (fondaparinux), 2.5 mg/day-what is bioavailability
    PhaseNot recorded
    Registry statusUnknown

  • Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

    NCT00436787 · start 2007-02

    Registered record
    Registry ID
    NCT00436787
    Conditions
    Venous Thrombosis; Pulmonary Embolism
    Interventions
    Fondaparinux Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2007-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thrombosis; Pulmonary Embolism
    InterventionFondaparinux Sodium
    PhasePhase 2
    Registry statusCompleted

  • Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

    NCT00423683 · start 2007-01

    Registered record
    Registry ID
    NCT00423683
    Conditions
    Cancer; Thromboembolism
    Interventions
    Arixtra alone; Arixtra + filter
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2007-01
    Completion
    2010-11
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Thromboembolism
    InterventionArixtra alone; Arixtra + filter
    PhasePhase 3
    Registry statusTerminated

  • Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

    NCT00412464 · start 2006-09

    Registered record
    Registry ID
    NCT00412464
    Conditions
    Thrombosis; Heparin-induced Thrombocytopenia
    Interventions
    Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-09
    Completion
    2009-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombosis; Heparin-induced Thrombocytopenia
    InterventionFondaparinux
    PhasePhase 1
    Registry statusCompleted

  • Study to Determine Effective Dosing of Fondaparinux in Obese Persons

    NCT00346879 · start 2006-08

    Registered record
    Registry ID
    NCT00346879
    Conditions
    Morbid Obesity
    Interventions
    fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2006-08
    Completion
    2009-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMorbid Obesity
    Interventionfondaparinux
    PhasePhase 1
    Registry statusWithdrawn

  • Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

    NCT00320424 · start 2006-02-16

    Registered record
    Registry ID
    NCT00320424
    Conditions
    Thromboembolism
    Interventions
    Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-02-16
    Completion
    2006-10-26
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolism
    InterventionFondaparinux
    PhasePhase 3
    Registry statusCompleted

  • Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

    NCT00252005 · start 2005-11

    Registered record
    Registry ID
    NCT00252005
    Conditions
    Deep-Vein Thrombosis
    Interventions
    Apixaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-11
    Completion
    2007-02
    Enrolment
    520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep-Vein Thrombosis
    InterventionApixaban
    PhasePhase 2
    Registry statusCompleted

  • Tranexamic Acid in HIp Fracture Surgery (THIF Study)

    NCT00327106 · start 2005-04

    Registered record
    Registry ID
    NCT00327106
    Conditions
    Hip Fracture
    Interventions
    Tranexamic acid (Exacyl); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-02
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHip Fracture
    InterventionTranexamic acid (Exacyl); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics of Fondaparinux in Patients With Major Orthopedic Surgery

    NCT01063543 · start 2004-09

    Registered record
    Registry ID
    NCT01063543
    Conditions
    Orthopedic Surgery
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-09
    Completion
    2007-02
    Enrolment
    997

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOrthopedic Surgery
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

    NCT00256100 · start 2004-06

    Registered record
    Registry ID
    NCT00256100
    Conditions
    Renal Failure
    Interventions
    Fondaparinux Sodium
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2004-06
    Completion
    2007-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Failure
    InterventionFondaparinux Sodium
    PhaseNot applicable
    Registry statusTerminated

  • OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

    NCT00064428 · start 2003-08

    Registered record
    Registry ID
    NCT00064428
    Conditions
    Thromboembolism
    Interventions
    fondaparinux - UFH not indicated; Control - UFH not indicated; Fondaparinux - UFH indicated; Control - UFH
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-08
    Completion
    2006-02
    Enrolment
    12,092

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolism
    Interventionfondaparinux - UFH not indicated; Control - UFH not indicated; Fondaparinux - UFH indicated; Control - UFH
    PhasePhase 3
    Registry statusCompleted